ERBB2 and breast carcinoma: Women with advanced hormone-receptor-positive and HER2 negative breast cancer eligible for therapy with alpelisib (active in patients with PIK3CA mutations), exhibit in the circulome (specifically in cDNA, EV and circulating tumor cells) PIK3CA mutations, mirroring the genomic alterations found in the corresponding cancer tissue [90].